BTOG Essential Update - Small Cell Lung Cancer: 2026 and Beyond

Wednesday 14th October 2026

Cavendish Conference Centre, The Minster Building, London

Approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 5 category 1 (external) CPD credits (code: 156323)

Programme

08:30	Registration-Refreshments-Exhibition	
09:00	Open – Welcome - Dr Tom Newsom-Davis, BTOG Steering Committee Chair	
Session 1	**Diagnosing and the Changing Face SCLC**	Chair: Tom Newsom-Davis (ENG)
09:10	SCLC State of the Nation: NLCA 2026	Neal Navani (ENG)
09:25	Histology and ctDNA in the Diagnosis of SCLC	Matthew Evans (ENG)
09:40	Need for Speed: Accelerating Diagnostic Pathways	Emma Halkyard (ENG)
09:55	Is Long-Term Survival in SCLC Achievable?	Riyaz Shah (ENG)
10:10	Panel	
10:30	Refreshments-Exhibition	
Session 2	**Limited Stage SCLC**	Chair: Samreen Ahmed (ENG)
11:00	What Is Resectable in SCLC?	Tom Combellack (WAL)
11:15	Optimising Thoracic Radiotherapy in Limited Stage	Hannah Bainbridge (ENG)
11:30	Getting Through: Patient Selection and Optimisation	Emma Wingate (ENG)
11:45	Adjuvant Therapies for Limited Stage SCLC	Shobhit Baijal (ENG)
12:00	Panel	
12:20	Lunch-Exhibition	
Session 3	**Metastatic SCLC**	Chair: Huiqi Yang (ENG)
13:00	Current Treatment Landscape for Metastatic SCLC	Samreen Ahmed (ENG)
13:20	T Cell Engagers	Sean Dulloo (ENG)
13:40	ADCs in SCLC: B7H3 and Beyond	Fiona Blackhall (ENG)
14:00	Panel	
14:20	Refreshments-Exhibition	
Session 4	**Controversies and Questions in SCLC**	Chair: Fiona Blackhall (ENG)
14:50	Do PCI and SRS Have a Role in SCLC?	Waleed Mohammed (ENG)
15:05	Emergence of Radiopharmaceutical in SCLC	Toby Talbot (ENG)
15:20	Thoracic Radiotherapy in Metastatic Disease	Huiqi Yang (ENG)
15:35	Panel	
16:00	Close	

BTOG Essential Update – Small Cell Lung Cancer: 2026 and Beyond is kindly sponsored by

AstraZeneca accord AMGEN Boehringer Ingelheim Roche

Sponsors have not been involved or influenced the content or agenda of this or any other BTOG education.

British Thoracic Oncology Group

Biographies

Samreen Ahmed, Professor, FRCP, MD, MBBS, MSc is a Consultant in Medical Oncology at the University Hospitals of Leicester NHS Trust, Leicester, UK, specialising in breast and lung cancer. She is also a Professor of Medical Oncology at the University of Leicester, Leicester, UK, and was appointed an Honorary Chair of Medical Oncology in 2016. In addition, she is the Training Programme Director for Medical Oncology and the Research Lead for both breast and lung cancer within the East Midlands Cancer Network. Samreen qualified in medicine in 1994 at the Royal Free Hospital School of Medicine, London, UK. She holds a research degree (MD) from Nottingham University, Nottingham, UK, and completed her oncology training at Weston Park Hospital, Sheffield, UK, Nottingham City Hospital, Nottingham, UK, and Leicester Royal Infirmary, Leicester, UK. She is a Fellow of the Royal College of Physicians.

Shobhit Baijal is a consultant medical oncologist based in Birmingham and an Honorary Professor at the University of Birmingham. He is an expert in the management of lung, bowel, and liver cancer, utilising techniques of immunotherapy, chemotherapy, and targeted therapy. Dr Baijal qualified from the University of London in 2001 and undertook training at St Bartholomew's Medical School while completing a bachelor's degree with honours in immunology and cell pathology at the University College London. He was appointed as a consultant at the University Hospitals Birmingham NHS Trust in 2011. In addition to his practice, Dr Baijal is heavily involved with clinical research and trials. He is the UK Chief and principal investigator for multiple national and international studies and works closely with pharmaceutical companies to develop new drugs for patient treatment. He also has extensive publications under his name, which he has presented at regional, national, and international cancer conferences. He is an invited medical expert for the National Institute for Health and Care Excellence (NICE) reviews of anti-cancer drug therapies and is a steering committee member of the British Thoracic Oncology Group, which supports and educates thoracic oncology professionals in the UK. Dr Baijal advises for charities EGFR Positive UK and ALK Positive UK and is on the expert panel for the Roy Castle Foundation.

Hannah Bainbridge, MBChB, MRCP, FRCR, PhD is Consultant Clinical Oncology at Portsmouth University Hospital. Hannah is also the SABR lead and Radiotherapy Research Lead.

Fiona Blackhall, Professor is a consultant medical oncologist and director of the research and innovation division at The Christie, and professor of thoracic oncology at The University of Manchester. In 1997, Professor Blackhall was awarded a Cancer Research Campaign PhD Fellowship for a clinician in the field of angiogenesis and in collaboration with Judah Folkman. In 2001, she undertook a clinical and post-doctoral fellowship at Princess Margaret Hospital and Ontario Cancer Institute in molecular pathology of lung cancer, biomarkers and drug development. Professor Blackhall is the clinical translational and biomarkers theme lead for the Cancer Research UK Lung Cancer Centre of Excellence. She has served as clinical lead of the Greater Manchester Cancer Genomics Pathway Board, clinical cancer lead of the North West NHS Genomics Laboratory Hub, NIHR GM Clinical Research Network Lung cancer lead, chair of the Advanced Disease Subgroup of the UK NCRI Lung Cancer Research Group, and co-chair of the Translational Subgroup of the European Thoracic Oncology Platform. She has been a faculty member for The European Society of Medical Oncology, The European Lung Cancer Conference, The American Society of Medical Oncology Annual Meeting and The International Association for the Study of Lung Cancer. In Manchester, since 2005, Professor Blackhall has created an environment for research spanning lung cancer biology, liquid biomarkers, novel therapies, phase I-III clinical trials, radiotherapy and supportive care with over 250 publications in these areas. She has collaborated with Professor Caroline Dive since 2007 on internationally leading research in circulating tumour cells. In 2020, Professor Blackhall received The ESMO/IASLC Heine H. Hansen Award which recognises outstanding contribution to lung cancer research and education. In 2021, she was appointed to director of the research and innovation division at The Christie to bring a strategy of operational transformation to accelerate access to an inclusive research portfolio. She is an advocate of team science and has enjoyed numerous collaborations with like-minded colleagues across the globe with the collective aim to make lung cancer a less deadly disease.

Tom Combellack is a Consultant Thoracic Surgeon at the University Hospital of Wales, Cardiff.

Sean Dulloo MBBS, MRCP, Msc is a Consultant Medical Oncologist and, current Head of Service for Oncology at the University Hospitals of Leicester NHS Trust. He completed his medical oncology training at Leicester. Prior to this he completed his Internal Medicine residency from the National University Health System, Singapore. Dr. Dulloo specialises in the management of thoracic cancers, hepatobiliary and neuroendocrine tumours. He is actively involved in research and clinical trials and has published in high impact journals such as Nature.

Matthew Evans is Consultant Cellular Pathologist specialising in biomarker/molecular, thoracic, gynaecological and gastrointestinal pathology at NHS Central and South Genomics Having grown up in the West Midlands, Matthew completed his undergraduate training at the University of Cambridge, where he studied Medical Sciences and East Asian Studies. Following this, he completed his training in Clinical Medicine at King's College London, qualifying in 2012. After short stint undertaking research at the University of Oxford, he started his training in cellular pathology at hospitals across the West Midlands, taking up his first position as a consultant cellular pathologist at Black Country Pathology Services in 2019. In 2021, he took up a consultant position in Southampton but continues to work for Black Country Pathology Services in a limited capacity. Matthew specialises in molecular, thoracic, gynaecological and gastrointestinal pathology. He sits on NHS England's Cancer Genomics Test Evaluation Working Group and is also a NICE appraiser for thoracic cancer treatments on behalf of the Royal College of Pathologists.

Emma Halkyard, based in Manchester, is currently a Lead Nurse for Networked Services and Advanced Nurse Practitioner Lung Cancer at The Christie NHS Foundation Trust. Emma Halkyard brings experience from previous roles at The Christie NHS Foundation Trust and Leeds Teaching Hospitals NHS Trust. Emma Halkyard holds a 2012 - 2014 Masters degree Advanced Practice in Advanced Practice Healthcare Oncology at The University of Salford.

Waleed Mohammed BA (Cantab), MSc (Oxon), MBBChir (Cantab), MRCP (Lond), FRCR is Consultant Oncologist at Imperial College Healthcare NHS Trust. Dr Mohammed initially trained as a bio-scientist, specialising in genetics at the University of Cambridge and completing an MSc in Biology at the University of Oxford, before delving into the pharmaceutical industry (Oxford Science Park and MRC Prion Unit at Queen Square, University College London). He subsequently re-trained as a medic (Cambridge Graduate Course in Medicine), specialising in clinical oncology, undertaking specialist registrar training at Imperial College NHS Trust, The Royal Marsden Hospital and The Royal Sussex County Hospital. He has been a consultant clinical oncologist at Charing Cross Hospital since 2020, where he introduced, developed and established the SABR radiotherapy service. He is a member of The Royal College of Physicians (London) and a Fellow of The Royal College of Radiologists (New Fellows Speaker award).

Professor Neal Navani qualified in Medicine from Cambridge University and UCL in 2000 with distinction and several University prizes. He trained in Respiratory Medicine at the Brompton and Hammersmith Hospitals before winning a Medical Research Council Fellowship in 2008 and completing his PhD at UCL in 2011. He has also completed an MSc in Clinical Trials and Biostatistics at the London School of Hygiene and Tropical Medicine. Professor Navani is lead clinician for the lung cancer service at UCLH, and senior clinical lead of the National Lung Cancer Audit. He is on the steering committee of the British Thoracic Oncology Group, UK Lung Cancer Coalition and on the Thoracic Oncology committee of the American Thoracic Society. Professor Navani currently holds >£2.5m of grant funding as chief investigator including a CRUK grant for the early diagnosis of lung cancer, a separate CRUK grant for developing novel methods for cancer data collection and NIHR funding for studies on predicting lung cancer prognosis with artificial intelligence and early detection of lung cancer in never smokers. He is an author of current NICE guidelines on lung cancer and bronchoscopy and co-chair of the BTS guideline on nodule management as well as a US guideline on peripheral bronchoscopy. He has over 150 peer-reviewed publications. In 2020, Dr Navani won a prestigious MRC / NIHR fellowship to research predictors of cancer in lung nodules and was appointed to Professor of Respiratory Medicine at UCL in 2024.

Tom Newsom-Davis – Chair, BTOG Steering Committee. Tom is a consultant thoracic medical oncologist at Chelsea and Westminster Hospital, London. He has an active clinical trials portfolio. He has been UK Chief Investigator for a number of studies, as well as chairing Independent Data Monitoring Committees and sitting on trial steering groups. He has published over 70 papers and presented more than 120 abstracts in national and international meetings. Tom joined the steering committee of BTOG in 2017. He serves on the Multidisciplinary Clinical Science Committee of the International Association for the Study of Lung Cancer (IASLC), on the Oncology Council of the Royal Society of Medicine, and as an invited clinic expert for NICE. Tom is past Chair of the RM Partners Cancer Alliance Lung group, and past member of the NCRI Lung Cancer Clinical Studies Group. Tom has been an invited lecturer for various organisations including the Royal College of Physicians, European Society of Medical Oncology (ESMO), IASLC, British Medical Association and the Association of Cancer Physicians. He has been a faculty member for ESMO and IASLC meeting. His work on Acute Diagnostic Oncology Clinics has previously been awarded a Macmillan Innovation Excellence Award.

Riyaz Shah is a Consultant Medical Oncologist at Kent Oncology Centre from 2006 to date. He qualified from Guy's and St Thomas Hospitals in 1994 and has been a member of the Royal College of Physicians of London since 1997. Other notable achievements include Imperial Cancer Research Fund Clinical Research Fellowship in 1998, PhD Imperial College 2002, ASCO Foundation Merit Award 2005, Medical Oncology training completed at Royal Marsden 2006, Elected to Fellowship of Royal College of Physicians of London 2010, Member of BTOG steering committee and Vice-chair BTOG 2026. Riyaz has been intimately involved in clinical trials over his career and is an early adopter and champion for liquid and tissue genomics in lung systemic therapy. As a steering committee member of BTOG he is extensively involved in organising and delivery of events at a national level and has recently taken the role of Vice-chair. As an active member of IASLC he supports the communications committee. He is a clinical advisor to the UK patient support/ advocacy groups "EGFR Lung Cancer UK", "UKALK+" and ROS1ders.

Toby Talbot is Consultant Clinical Oncologist in Cornwall. Toby specialises in treating thoracic malignancies and skin cancer. He has been involved in clinical research for many years, with a special interest in immunotherapy. He has been PI on over 40 studies and national CI for six trials.

Emma Wingate is Therapeutic Lung Consultant Radiographer at University Hospitals Birmingham NHS Foundation Trust.

Huiqi Yang is Consultant Clinical Oncologist at Cambridge University Hospitals NHS Foundation Trust.